All News

A new study sponsored by the Biotechnology Industry Organization (BIO) insists that new drugs and biologics will have a minor impact on total healthcare expenditures over the next five years.

The FDA announced the availability of a draft guidance designed to assist the research community in interpreting requirements for submitting reports of unanticipated problems such as certain adverse events reports to Institutional Review Board (IRB).

An estimated three out of five people with Type 2 diabetes have at least one of the other serious health problems commonly associated with the disease.

An educational program is now available to help patients learn to self-administer Vivaglobin, the first subcutaneously administered immunoglobulin for the treatment of primary immunodeficiency.

RediClinicLLC has entered into a 50-50 partnership with Memorial Hermann, called RCMH LLC, for the operation of all RediClinics in the Greater Houston area.

Can a marriage between a highly automated pharmacy chain that operates in grocery stores and a company that provides home care services and operates retail health clinics be successful?

AVA Pharmaceuticals announced that it has settled a patent infringement suit with Impax Laboratories and Purdue Pharma regarding Impax's generic versions of Purdue's OxyContin.

The FTC launched a civil investigation requesting that Bristol-Myers Squibb turn over key documents and information surrounding a reverse-payment deal it and Sanofi-Aventis made with generic firm Apotex to delay market entry of generic clopidogrel bisulfate (Plavix).

A new report from the Campaign for America's Future argues that Medicare Part D and beneficiaries would save $30 billion in prescription drug costs if the federal government negotiated Medicare drug prices with pharmaceutical companies.